Achieve Life Sciences, Inc. ACHV

ACHV Company Overview

Achieve Life Sciences, Inc. (Nasdaq: ACHV) is a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for nicotine dependence and smoking cessation. The company operates within the biotechnology and pharmaceutical industries, with its primary emphasis on addressing tobacco addiction through prescription therapeutics. Achieve’s lead and principal asset is cytisinicline, a plant-based nicotinic acetylcholine receptor partial agonist being developed as a treatment for smoking cessation and nicotine dependence, including combustible cigarettes and vaping products. The company’s revenue profile has historically been limited because it remains in the clinical development stage and has not yet commercialized an approved product.

Achieve Life Sciences was formed through the merger of OncoGenex Pharmaceuticals and Achieve Life Sciences in 2017, creating a company centered on addiction therapeutics rather than oncology. Since the merger, the company has concentrated resources on advancing cytisinicline through clinical trials and regulatory pathways. Achieve’s positioning is differentiated by its focus on a historically underserved smoking cessation market, particularly given ongoing global public health efforts to reduce nicotine addiction and the limited number of approved pharmacologic cessation therapies currently available.